A mainstay of cancer treatment, doxorubicin is used as a standalone agent or in combination therapies, on-label and off, in at least 14 cancer types, including breast cancer, non-small cell lung cancer, and Wilms tumor.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
